Scholars Central

Conference abstractPublished 5 Apr 2022

Limitations of Adulhelm for treatment of mild cognitive impairment of Alzheimer's Disease (AD), opens new avenues for other promising treatment candidates

Authors: Girish J. Kotwal

Kotwal Bioconsulting, USA

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Aduhelm/Aducanumab is an amyloid beta-directed monoclonal antibody indicated to treat Alzheimer's disease. Aduhelm is approved under the accelerated approval pathway by US FDA. There are multiple limitations in the use of Aduhelm.It is unclear how effective Aduhelm is when it is transfused intravenously (IV) once a month for one hour each time. 2) The initial cost was estimated to be $56,000/year/patient. Later the cost was halved. No idea how many could qualify for Medicare coverage. Could be a million with early stage memory loss or cognitive deficit. 3) Those with moderate to severe cases will not qualify. 4) There are other FDA approved drugs for early stage Alzheimer's disease (AD). 5) The goal of the Aduhelm is to reduce beta amyloid and tau fibril formation or accumulation requiring monitoring with sophisticated imaging that is not cheap. 8) There is no clear assessment of the adverse effects of pushing a monoclonal antibody passed the delicate aging blood brain barrier. 9) Not sure whether the concerns of 2 members of the FDA panel who resigned have been addressed. 10) It is well known that AD patients need considerable care and caring for a patient receiving Aduhelm will add to the care required. There could have been much better ways to deliver Aduhelm that were not tried before choosing the IV route. Also, there are other candidates like vaccinia virus complement control protein (VCP) that can target the harmful effects of amyloid and even prevent death that Aduhelm has been reported to cause. VCP can block both pathways of complement activation and prevent formation of pro-inflammatory chemotactic factors, C3a and C5a and bring about neuroprotection. Extensive pre-clinical studies have confirmed VCP as an ideal candidate to treat AD in humans.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Alzheimers Disease & Parkinsonism
  • SubjectNeuroscience & Neurology
  • BylineArticles whose byline prints “Girish J. Kotwal”